<DOC>
	<DOCNO>NCT00610714</DOCNO>
	<brief_summary>The main purpose study determine AZD0530 improve efficacy standard chemotherapy treatment ovarian cancer</brief_summary>
	<brief_title>AZD0530 Phase II Study Patients With Advanced Ovarian Cancer</brief_title>
	<detailed_description />
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Saracatinib</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>Have diagnosis advanced ovarian cancer Have evidence recurrence disease progression least 6 month follow treatment cessation 1st 2nd line platinum contain therapy Estimated life expectancy 12 week Central Nervous System ( CNS ) metastases Received 2 prior chemotherapy regimens ovarian cancer treatment Inadequate bone marrow reserve Inadequate liver function , renal function low haemoglobin Pregnant , breastfeed childbearing status unwilling use acceptable method contraception</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2012</verification_date>
	<keyword>Cancer</keyword>
	<keyword>Tumour</keyword>
	<keyword>Ovarian Neoplasms</keyword>
	<keyword>Ovarian Cancer</keyword>
</DOC>